Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes
Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes
复制标题
DOI：
10.1016/j.atherosclerosis.2015.06.001
复制
发表时间：
2015-08-01
期刊：
影响因子：
5.3
通讯作者：
Ray, Kausik K.
中科院分区：
文献类型：
--
作者：
Vallejo-Vaz, Antonio J.;Seshasai, Sreenivasa Rao Kondapally;Ray, Kausik K.
目的：他汀类药物对血脂指数的不良反应是否在所有他汀类药物中均存在争议，目前关于匹伐他汀的数据有限。我们试图评估匹伐他汀对非糖尿病个体的高血压和新发糖尿病（NOD）的影响，使用通过荟萃分析汇总的RCT数据。材料和方法：我们搜索了医疗热线，科克伦，Embase和临床试验注册网站，直至2014年11月，用于>= 12周随访安慰剂或他汀类药物-匹伐他汀的对照RCT，包括无糖尿病的受试者，并报告空腹血糖（FBG）、HbA 1c或NOD。我们还通过咨询Kowa Ph. Ltd.寻求研究。通过随机效应荟萃分析估计匹伐他汀与结局的相关性。通过I-2统计量、敏感性和亚组分析以及漏斗图和Egger和Harbord检验的发表偏倚评估异质性。1600人年）。与匹伐他汀无显著差异（与对照组相比）观察FBG（MD -0.01 mg/dL [95% CI-0.77，0.74]，I-2 = 0%），HbA1c（MD-0.03%[95% CI-0.11，0.05]，I-2 = 43%）或NOD（RR 0.70 [95% CI 0.30，1.61]; RD 0.0 [95% CI-0.004，0.003]; I-2 = 0%）。敏感性和亚组分析（包括对照类型[安慰剂或其他他汀类药物]、匹伐他汀剂量或随访）未产生显著结果。NOD.Conclusions：在目前的荟萃分析中，匹伐他汀与安慰剂或其他他汀类药物相比，对葡萄糖代谢或糖尿病的发展没有不良影响。(C)2015爱思唯尔爱尔兰有限公司版权所有。
Aims: Whether adverse effect of statins on glycaemic indices is common to all statins remains controversial and as yet data for pitavastatin are limited. We sought to assess the effects of pitavastatin on glycaemia and new-onset diabetes (NOD) in non-diabetic individuals using data from RCT pooled together by means of a meta-analysis.Materials and methods: We searched Medline, Cochrane, Embase and clinical trials registries websites until November-2014 for >= 12-week follow-up placebo or statin-controlled RCT of pitavastatin that included participants without diabetes and reported on fasting blood glucose (FBG), HbA1c or NOD. We additionally sought studies by consulting with Kowa Ph. Ltd. The association of pitavastatin with the outcomes were estimated by random-effects meta-analyses. Heterogeneity was assessed by the I-2 statistic and sensitivity and subgroup analyses, and publication bias with funnel plots and Egger and Harbord Tests.Results: 15 studies (approx. 1600 person-years) were included. No significant differences associated with pitavastatin (vs. control) were observed for FBG (MD -0.01 mg/dL [95% CI -0.77, 0.74], I-2 = 0%), HbA1c (MD -0.03% [95% CI -0.11, 0.05], I-2 = 43%) or NOD (RR 0.70 [95% CI 0.30, 1.61]; RD 0.0 [95% CI -0.004, 0.003]; I-2 = 0%). Sensitivity and subgroup analyses (including type of control [placebo or other statin], pitavastatin dose or follow-up] did not yield significant results. Potential publication bias may occur for NOD.Conclusions: In the present meta-analysis pitavastatin did not adversely affect glucose metabolism or diabetes development compared with placebo or other statins. (C) 2015 Elsevier Ireland Ltd. All rights reserved.